|
|
||||||||
TRANSLATIONAL PHYSIOLOGY
1Department of Biology, Saint Louis University, St. Louis 63103; 2Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis 63110; 3American Parkinson Disease Association Advanced Center for Parkinson Research, St. Louis, Missouri 63110
Submitted 13 November 2003 ; accepted in final form 12 July 2004
ABSTRACT
We hypothesized that levodopa with carbidopa, a common therapy for patients with Parkinson's disease, might contribute to the high prevalence of insulin resistance reported in patients with Parkinson's disease. We examined the effects of levodopa-carbidopa on glycogen concentration, glycogen synthase activity, and insulin-stimulated glucose transport in skeletal muscle, the predominant insulin-responsive tissue. In isolated muscle, levodopa-carbidopa completely prevented insulin-stimulated glycogen accumulation and glucose transport. The levodopa-carbidopa effects were blocked by propranolol, a
-adrenergic antagonist. Levodopa-carbidopa also inhibited the insulin-stimulated increase in glycogen synthase activity, whereas propranolol attenuated this effect. Insulin-stimulated tyrosine phosphorylation of insulin receptor substrate (IRS)-1 was reduced by levodopa-carbidopa, although Akt phosphorylation was unaffected by levodopa-carbidopa. A single in vivo dose of levodopa-carbidopa increased skeletal muscle cAMP concentrations, diminished glycogen synthase activity, and reduced tyrosine phosphorylation of IRS-1. A separate set of rats was treated intragastrically twice daily for 4 wk with levodopa-carbidopa. After 4 wk of treatment, oral glucose tolerance was reduced in rats treated with drugs compared with control animals. Muscles from drug-treated rats contained at least 15% less glycogen and
50% lower glycogen synthase activity compared with muscles from control rats. The data demonstrate
-adrenergic-dependent inhibition of insulin action by levodopa-carbidopa and suggest that unrecognized insulin resistance may exist in chronically treated patients with Parkinson's disease.
Parkinson's disease; insulin resistance; diabetes; dopamine
This article has been cited by other articles:
![]() |
J. L. Smith, P. B. Patil, S. D. Minteer, J. R. Lipsitz, and J. S. Fisher Possibility of Autocrine {beta}-Adrenergic Signaling in C2C12 Myotubes Experimental Biology and Medicine, December 1, 2005; 230(11): 845 - 852. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |